Cullinan Oncology Adds Industry Leaders to Board, Bringing Significant Business & Healthcare Acumen

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Cullinan Oncology, a company dedicated to significantly enhancing the standard of care in cancer by shepherding breakthrough science, announced today the appointment of Thomas Ebeling and Tony Rosenberg to its Board of Directors.

“We are fortunate to have both Thomas and Tony join the Cullinan board. Their collective experience in healthcare and beyond will be invaluable as we scale the company and build our pipeline of novel cancer therapies,” said Owen Hughes, Cullinan CEO.

Thomas Ebeling is a standing member of the UBS Oncology Impact Fund (OIF) managed by MPM Capital. He is also CEO of ProSiebenSat.1 Media SE, one of Europe’s largest mass media companies; a member of the supervisory board of Bayer AG; and a member of the advisory boards of Sivantos, a world leading hearing aid company, and GFK, a leading market research company. From 2000 to 2007, Thomas was CEO of the global Novartis pharmaceuticals business where, under his leadership, the company’s revenues more than doubled from $11B to nearly $23B. Before that, he was responsible for the leadership of the Novartis Nutrition division where he headed three business units.

“I’m excited to join Cullinan given the accelerating pace of scientific innovation in oncology,” stated Mr. Ebeling. “I look forward to working with this talented group to unlock the promise of new technologies and usher in the next wave of improved outcomes for those living with cancer.”

Tony Rosenberg is a managing director at MPM Capital where he is a board member at portfolio companies Clinical Ink, iOmx Therapeutics, Radius, and TriNetX. He is also an independent board member of argenx. Prior to MPM Capital, he was Global Head, M&A and Licensing at Novartis where he oversaw the Novartis portfolio transformation, a comprehensive set of transactions, to focus the company on its global businesses in innovative pharmaceuticals, eye care, and generics. Tony joined Novartis via its predecessor company Sandoz where he held diverse leadership positions in sales and marketing, business development and strategic planning.

“I’m delighted to join the board of directors of Cullinan Oncology,” said Mr. Rosenberg. “The combination of a world class management team and a truly innovative operational model will, I believe, lead to the development of real breakthroughs in cancer therapy and, most importantly, better outcomes for patients.”

About Cullinan
Cullinan Oncology is focused on investing in and developing a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model. Sourced from the Cullinan dry lab as well as external collaborators, the company’s assets are managed by a single, highly experienced team of oncology professionals and drug developers across a lean, capital efficient operating model. Cullinan is backed by the UBS Oncology Impact Fund (OIF) managed by MPM Capital, a worldwide leader in oncology investing, and F2 Ventures. For additional information, please visit www.cullinanoncology.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171129005688/en/